Centre awarded three CIHR Project Grants in Fall 2016 competition
Congratulations to Drs. Collins, Daugaard & Wang on being awarded five-year grants in the CIHR Project Grant: Fall 2016 competition. Dr. Wang is also a co-investigator on a five-year grant awarded to Dr. He at University Health Network (Toronto). Congratulations also to Dr. William Morris of the BC Cancer Agency and his research team, including our Centre's Dr. Alan So, on being awarded a six-year grant in the same competition.
Drug created from malaria parasite shows promise as bladder cancer treatment
UBC Media release: April 20, 2017
A drug created from a malaria protein stopped tumour growth of chemotherapy-resistant bladder cancer, offering hope for cancer patients not responding to standard treatments.
NEPC is a highly aggressive cancer that sometimes emerges in prostate cancer patients undergoing androgen deprivation therapy (ADT). Unfortunately ADT, which is common treatment for prostate cancer, had led to a correlating increase in cases of an aggressive variant called treatment-induced NEPC.
My Precision Oncology Program featured in VCHRI Research Insider
The VPC's My Precision Oncology Program (MyPOP) is the lead story in the Nov. 22, 2016 issue of Research Insider, the Vancouver Coastal Health Research Institute's newsletter. The article includes an interview with Dr. Kim Chi, Associate Director of Clinical Research at our Centre. Read the full article here (opens in new window).
MyPOP featured in the VCHRI Research Insider
The My Precision Oncology Program (MyPOP) is the lead story in the November 22, 2016 issue of Research Insider, the Vancouver Coastal Health Research Institute's newsletter. Read the full article here (opens in new window).
OncoGenex Pharmaceuticals Inc. has announced positive survival results from the final analysis of the Apatorsen Phase 2 Borealis-2™ trial in metastatic bladder cancer. Apatorsen (OGX-427) was discovered at the VPC and outlicensed to OncoGenex. The full press release is below; click here for the original article on PR Newswire (opens in new window).
May 18, 2016, Vancouver, B.C – BGI, headquartered in China, and the Vancouver Prostate Centre (VPC) signed a memorandum of understanding to bring together advanced and cost effective sequencing, genomics and computing technologies of BGI with the world class translational cancer research and drug development program at the VPC.
Roche licensing agreement profiled in Networks of Centres of Excellence of Canada impact story
The Networks of Centres of Excellence (NCE) of Canada published an impact story about the recent licensing agreement between Roche and UBC. It describes PC-TRiADD's role in assisting the transition from discovery to intellectual property (IP) to commercialization.
Click here to read the article at the NCE's website.
Potential prostate cancer treatment developed in B.C. gets big boost
A potential treatment for advanced prostate cancer developed by the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute (VCHRI) scientists has been licensed to pharmaceutical company Roche, marking UBC’s largest licensing agreement to date.
Destructive disease shows potential as a cancer treatment
Scientists at the University of British Columbia, Vancouver Coastal Health and the BC Cancer Agency have discovered a protein from malaria that could one day help stop cancer in its tracks.
This new approach, which halted the growth of various tumours in mice, was based on a discovery by collaborators at the University of Copenhagen. While exploring why pregnant women are particularly susceptible to malaria, they found that the mosquito-borne parasite produces a protein that binds to a particular type of sugar molecule in the placenta.